Tinea Corporis Caused by Microsporum Canis in Children with HIV
DOI:
https://doi.org/10.66344/jpad.v32i4.1998Abstract
Introduction: Tinea corporis is a glabrous skin fungal infection mainly affecting children and immunosuppressed patients. The clinical feature of tinea in HIV patients shows mild inflammation that resembles other dermatoses. This report aims to establish the diagnosis and therapy choices promptly. Case: A 15-year-old boy with HIV and pulmonary TB came with complaints of itchy small red papules, exacerbated by sweating. These lesions extend almost all over the body. Dermatological examination of the chest, abdomen, back, arms and hands, and both legs showed multiple erythematous papules with annular configuration and the elevated border with scales over the erythematous base. KOH examination revealed the culture's long septate hyphae and colonies of the fungus Microsporum canis. Tinea corporis was diagnosed, and the patient was treated with oral griseofulvin and topical ketoconazole. Discussion: Microsporum canis is the third most common causative organism and is associated with 14% of cases of tinea corporis. These annular lesions resemble centrifugal erythema annular and generalized annular granulomas. A fungal culture examination was performed to confirm the diagnosis, and the tinea species were identified. Terbinafine, itraconazole, fluconazole and griseovulfin are the treatment options for tinea corporis with HIV. Conclusion: Definitive diagnosis and exact identification of the causative organism of tinea corporis could be determined by culture. Griseofulvin is still used to treat tinea, especially in liver function problems.
References
1. Craddock L, Schieke S. Superficial Fungal Infection. 2019. In: Fitzpatrick 9th ed [Internet]. New York: McGraw-Hill Education; [2925-51].
2. Roderick J, Ashbee H. Fungal Infection. 2016. In: Rook’s Textbook of Dermatology [Internet]. John Wiley & Sons, Ltd. 9th. [32.18-32.50].
3. Costa J, Neves R, Delgado M, Lima-Neto R, Morais V, et al. Dermatophytosis in patients with human immunodeficiency virus infection: Clinical aspects and etiologic agents. Acta Trop. 2015;150:111-5.
4. Ali S, Gajjala S, Raj A. Study of prevalence of dermatophytes among human immunodeficiency virus/AIDS patients in Shadan Institute of Medical Sciences and Teaching Hospital and Research Centre, Hyderabad, Telangana, India.. 2018;39:98-101. Indian J Sex Transm Dis. 2018;39:98-101.
5. Carod J, Ratsitorahina M, Raherimandimby V, Vitrat V, Andrianaja V, et al. Outbreak of Tinea capitis and corporis in a primary school in Antananarivo, Madagascar. J Infect Dev Ctries. 2011;5(10):732-6.
6. Yassine M, Haiet A-H, Narjess T-D, Zohra SM. Tinea Corporis Caused by Microsporum Canis in HIV Patient Treated For Neuromeningeal Cryptococcis: Report of A Nosocomial Outbreak. J Curr Med Res Opin. 2018;1(4):16-8.
7. Qadim H, Golforoushan F, Azimi H, Goldust M. Factors leading to dermatophytosis. Ann Parasitol. 2013;59(2):99-102.
8. Keiler S, Ghannoum M. Dermatophytosis. 2010. In: Antifungal therapy [Internet]. New York: Informa Healthcare; [258-77].
9. Lo Re V r, Carbonari D, Lewis J, Forde K, Goldberg D, et al. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status. Am J Med Genet. 2017;129(3):283-91.e5.
10. Khoza S, Moyo I, Ncube D. Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats. J Toxicol. 2017;2017:1-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Sri Mariyani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
